Search | Clinical Trials Finder

Conditions: Down Syndrome, Cardiovascular Risk Factor, Atherosclerosis
Interventions: Evaluate vascular disease risk factors in children with Down Syndrome, Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome; Other
Lead sponsor: University of Utah; Other
Eligibility: 10 Years to 18 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Down Syndrome
Interventions: Hip Helpers home program; Other
Lead sponsor: University of St. Augustine for Health Sciences; Other
Eligibility: 3 Months to 15 Months
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: San Marcos, California • Saint Augustine, Florida • Austin, Texas

Conditions: Down Syndrome, Polyendocrinopathies, Autoimmune, Respiratory Tract Infections, Autoimmunity
Interventions: Phlebotomy; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 22 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Down Syndrome, Cognitive Dysfunction
Interventions: Aricept (Donepezil hydrochloride), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 6 Years to 10 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: San Antonio, Texas • Herndon, Virginia

Conditions: Obstructive Sleep Apnea, Down Syndrome
Interventions: Atomoxetine and oxybutynin (ato-oxy); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 6 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Aortopathies, Thoracic Aortic Aneurysm, Aortic Valve Disease, Thoracic Aortic Disease, Thoracic Aortic Dissection, Thoracic Aortic Rupture, Ascending Aortic Disease, Descending Aortic Disease, Ascending Aortic Aneurysm, Descending Aortic Aneurysm, Marfan Syndrome, Loeys-Dietz Syndrome, Vascular Ehlers-Danlos Syndrome, Shprintzen-Goldberg Syndrome, Turner Syndrome, PHACE Syndrome, Autosomal Recessive Cutis Laxa, Congenital Contractural Arachnodactyly, Arterial Tortuosity Syndrome, Bicuspid Aortic Valve-Associated Aortopathy, Bicuspid Aortic Valve, Familial Thoracic Aortic Aneurysm and Aortic Dissection
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2030
U.S. locations: 2
States / cities: Atlanta, Georgia • Indianapolis, Indiana

Conditions: Turner Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 22 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Klinefelter Syndrome
Interventions: Fenofibrate 145 mg; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 15 Years to 40 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Down Syndrome
Interventions: Rivastigmine, Liquid Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Turner's Syndrome
Interventions: Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 138 Months to 13 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Fragile X Syndrome
Interventions: STX107; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Marfan Syndrome, Loeys-Dietz Syndrome, Thoracic Aortic Aneurysm and Dissection Syndromes, Ehlers-Danlos Type IV Syndrome, Turner Syndrome
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Days to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Down Syndrome
Interventions: GENUS device (Active Settings), GENUS device (Sham Settings); Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Down Syndrome
Interventions: ELND005, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: La Jolla, California • Orange, California • Boston, Massachusetts

Conditions: Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Down Syndrome (Trisomy 21), Edward's Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), Klinefelter Syndrome (47, XXY), and Other Chromosome, Abnormalities.
Interventions: Not listed
Lead sponsor: Lenetix Medical Screening Laboratory; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 7
States / cities: Rockville, Maryland • Moristown, New Jersey • Mineola, New York + 3 more

Conditions: Turner Syndrome
Interventions: Somatropin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 9 Months to 4 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 10
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 7 more

Conditions: Fragile X Syndrome
Interventions: AFQ056; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Nashville, Tennessee

Conditions: Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis, Hamartoma Syndrome, Multiple, Fragile X Syndrome, Angelman Syndrome, Rett Syndrome, Chromosome 15Q, Partial Deletion, Creatine Deficiency, X-linked
Interventions: Functional Behavioral Training (FBT), Positive Parenting Strategies-Treatment as Usual; Behavioral · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 2 Years to 12 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Angelman Syndrome
Interventions: GTX-102; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Los Angeles, California • San Diego, California • Atlanta, Georgia + 3 more

Conditions: Down Syndrome, Postural Balance
Interventions: Strider Balance Bike; Other
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 5 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Flowood, Mississippi

Conditions: Down Syndrome, Alzheimer Disease
Interventions: Remote Low, Remote High, Personal Coach; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Fragile X Syndrome
Interventions: Aripiprazole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 35 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability, Autism Spectrum Disorder, Hypotonia, Inborn Errors of Metabolism, Movement Disorders, Genetic Disease, Development Delay, Chromosome Abnormality, Hearing Loss, Dysmorphic Features, Skeletal Dysplasia, Congenital Abnormality, Microcephaly, Macrocephaly
Interventions: Pre-visit prep, usual care + exome seq; Behavioral · Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 0 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Asheville, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina

Search by objective public record fields.

Vascular Health and Risk Factors in Children With Down Syndrome

Impact of an Orthotic Garment on Gross Motor Skills for Infants With Down Syndrome

Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

Medications for Obstructive Sleep Apnea In Children With Down Syndrome

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

Risk of Diabetes in Young Turner Syndrome Patients

Interrogating Fatty Acid Metabolism Impairment and Clinical Correlates in Males with Klinefelter Syndrome

Rivastigmine Study in Adolescents With Down Syndrome

Initiating Transdermal Estradiol Therapy in Turner's Syndrome

A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes

Gamma Frequency Stimulation in Individuals With Down Syndrome

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

Natural History of Noncirrhotic Portal Hypertension

Non-Invasive Determination of Fetal Chromosome Abnormalities

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)

A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

Balance Bike Training in Down Syndrome

The Promotion of Physical Activity for the Prevention of Alzheimer's Disease in Adults With Down Syndrome

A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2